vs
Alpha Teknova, Inc.（TKNO）与TRINITY BIOTECH PLC（TRIB）财务数据对比。点击上方公司名可切换其他公司
TRINITY BIOTECH PLC的季度营收约是Alpha Teknova, Inc.的3.1倍（$30.5M vs $10.0M）。TRINITY BIOTECH PLC净利率更高（-33.0% vs -47.7%，领先14.7%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-4.1M）
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
Trinity Biotech PLC是一家全球体外诊断企业，研发、生产和销售适用于临床实验室与床旁检测场景的诊断试剂盒及配套系统，产品线覆盖糖尿病管理、传染病、心脏健康、自身免疫疾病等领域，主要市场包括北美、欧洲及全球新兴经济体。
TKNO vs TRIB — 直观对比
营收规模更大
TRIB
是对方的3.1倍
$10.0M
净利率更高
TRIB
高出14.7%
-47.7%
自由现金流更多
TKNO
多$3.2M
$-4.1M
损益表 — Q4 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $10.0M | $30.5M |
| 净利润 | $-4.8M | $-10.1M |
| 毛利率 | 32.5% | 36.8% |
| 营业利润率 | -46.2% | -23.2% |
| 净利率 | -47.7% | -33.0% |
| 营收同比 | 7.8% | — |
| 净利润同比 | 16.8% | — |
| 每股收益（稀释后） | $-0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TKNOTRIB
| Q4 25 | $10.0M | — | ||
| Q3 25 | $10.5M | — | ||
| Q2 25 | $10.3M | — | ||
| Q1 25 | $9.8M | — | ||
| Q4 24 | $9.3M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $9.6M | $30.5M | ||
| Q1 24 | $9.3M | — |
净利润TKNOTRIB
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-4.3M | — | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $-4.6M | — | ||
| Q4 24 | $-5.7M | — | ||
| Q3 24 | $-7.6M | — | ||
| Q2 24 | $-5.4M | $-10.1M | ||
| Q1 24 | $-8.1M | — |
毛利率TKNOTRIB
| Q4 25 | 32.5% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 38.7% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 29.2% | 36.8% | ||
| Q1 24 | 23.8% | — |
营业利润率TKNOTRIB
| Q4 25 | -46.2% | — | ||
| Q3 25 | -38.4% | — | ||
| Q2 25 | -32.9% | — | ||
| Q1 25 | -50.7% | — | ||
| Q4 24 | -60.7% | — | ||
| Q3 24 | -77.6% | — | ||
| Q2 24 | -53.0% | -23.2% | ||
| Q1 24 | -86.0% | — |
净利率TKNOTRIB
| Q4 25 | -47.7% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -34.7% | — | ||
| Q1 25 | -47.4% | — | ||
| Q4 24 | -61.7% | — | ||
| Q3 24 | -79.0% | — | ||
| Q2 24 | -55.8% | -33.0% | ||
| Q1 24 | -87.2% | — |
每股收益（稀释后）TKNOTRIB
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | $-0.09 | — | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.3M | $5.3M |
| 总债务越低越好 | $13.1M | — |
| 股东权益账面价值 | $68.8M | $-29.4M |
| 总资产 | $103.6M | $94.4M |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资TKNOTRIB
| Q4 25 | $21.3M | — | ||
| Q3 25 | $22.1M | — | ||
| Q2 25 | $24.0M | — | ||
| Q1 25 | $26.3M | — | ||
| Q4 24 | $30.4M | — | ||
| Q3 24 | $31.7M | — | ||
| Q2 24 | $18.6M | $5.3M | ||
| Q1 24 | $21.6M | — |
总债务TKNOTRIB
| Q4 25 | $13.1M | — | ||
| Q3 25 | $13.1M | — | ||
| Q2 25 | $13.0M | — | ||
| Q1 25 | $13.0M | — | ||
| Q4 24 | $9.4M | — | ||
| Q3 24 | $10.9M | — | ||
| Q2 24 | $12.3M | — | ||
| Q1 24 | $13.2M | — |
股东权益TKNOTRIB
| Q4 25 | $68.8M | — | ||
| Q3 25 | $72.7M | — | ||
| Q2 25 | $76.1M | — | ||
| Q1 25 | $78.6M | — | ||
| Q4 24 | $82.4M | — | ||
| Q3 24 | $87.3M | — | ||
| Q2 24 | $78.9M | $-29.4M | ||
| Q1 24 | $83.4M | — |
总资产TKNOTRIB
| Q4 25 | $103.6M | — | ||
| Q3 25 | $107.6M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $114.0M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $124.1M | — | ||
| Q2 24 | $115.4M | $94.4M | ||
| Q1 24 | $120.8M | — |
负债/权益比TKNOTRIB
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-462.0K | $-3.9M |
| 自由现金流经营现金流 - 资本支出 | $-810.0K | $-4.1M |
| 自由现金流率自由现金流/营收 | -8.1% | -13.3% |
| 资本支出强度资本支出/营收 | 3.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.8M | $-4.1M |
8季度趋势，按日历期对齐
经营现金流TKNOTRIB
| Q4 25 | $-462.0K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | $-936.0K | — | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-2.8M | $-3.9M | ||
| Q1 24 | $-6.6M | — |
自由现金流TKNOTRIB
| Q4 25 | $-810.0K | — | ||
| Q3 25 | $-2.4M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-3.0M | $-4.1M | ||
| Q1 24 | $-6.7M | — |
自由现金流率TKNOTRIB
| Q4 25 | -8.1% | — | ||
| Q3 25 | -22.6% | — | ||
| Q2 25 | -22.4% | — | ||
| Q1 25 | -44.0% | — | ||
| Q4 24 | -16.2% | — | ||
| Q3 24 | -25.0% | — | ||
| Q2 24 | -30.7% | -13.3% | ||
| Q1 24 | -71.8% | — |
资本支出强度TKNOTRIB
| Q4 25 | 3.5% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 1.2% | 0.5% | ||
| Q1 24 | 1.2% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
TRIB
暂无分部数据
